143 related articles for article (PubMed ID: 12667341)
41. Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma--EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54).
Aurer I; Eghbali H; Raemaekers J; Khaled HM; Fortpied C; Baila L; van der Maazen RW;
Eur J Haematol; 2011 Feb; 86(2):111-6. PubMed ID: 20942843
[TBL] [Abstract][Full Text] [Related]
42. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
43. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract.
Dodd PM; McCaffrey JA; Hilton S; Mazumdar M; Herr H; Kelly WK; Icasiano E; Boyle MG; Bajorin DF
J Clin Oncol; 2000 Feb; 18(4):840-6. PubMed ID: 10673526
[TBL] [Abstract][Full Text] [Related]
44. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma.
Bernell P; Ohm L
Br J Haematol; 1998 Apr; 101(1):203-4. PubMed ID: 9576202
[TBL] [Abstract][Full Text] [Related]
45. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
46. High-dose cytosine-arabinoside and cisplatin regimens as salvage therapy for refractory or relapsed AIDS-related non-Hodgkin's lymphoma.
Bi J; Espina BM; Tulpule A; Boswell W; Levine AM
J Acquir Immune Defic Syndr; 2001 Dec; 28(5):416-21. PubMed ID: 11744828
[TBL] [Abstract][Full Text] [Related]
47. Intermediate dose gemcitabine-cisplatin combination chemotherapy without treatment delay for cytopenia followed by autografting--a new standard of care in relapsed or refractory Hodgkin lymphoma?
Todd T; Raj S; Camilleri D; Stafford G; Bulusu R; Follows G; Williams M; Marcus R
Ann Hematol; 2009 Nov; 88(11):1107-12. PubMed ID: 19418054
[TBL] [Abstract][Full Text] [Related]
48. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.
Josting A; Rudolph C; Reiser M; Mapara M; Sieber M; Kirchner HH; Dörken B; Hossfeld DK; Diehl V; Engert A;
Ann Oncol; 2002 Oct; 13(10):1628-35. PubMed ID: 12377653
[TBL] [Abstract][Full Text] [Related]
49. Salvage chemotherapy according to the ASHAP protocol: a single-center study of 24 patients with relapsed or refractory aggressive non-Hodgkin's lymphomas.
Nückel H; Dürig J; Dührsen U
Ann Hematol; 2003 Aug; 82(8):481-486. PubMed ID: 12910375
[TBL] [Abstract][Full Text] [Related]
50. Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: a prospective randomized trial in Algeria.
Aribi M; Mesli N; Remla N; Sari BE; Taleb A; Touhami H; Bekadja MA; Zouaoui-Benhadji Z; Bouzid K; Meguenni K
J Cancer Res Ther; 2010; 6(1):41-6. PubMed ID: 20479546
[TBL] [Abstract][Full Text] [Related]
51. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's Lymphoma Study Group.
Bredenfeld H; Franklin J; Nogova L; Josting A; Fries S; Mailänder V; Oertel J; Diehl V; Engert A;
J Clin Oncol; 2004 Jun; 22(12):2424-9. PubMed ID: 15136597
[TBL] [Abstract][Full Text] [Related]
52. Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens.
Sánchez-Escribano Morcuende R; Alés-Martínez JE; Aramburo González PM
Clin Transl Oncol; 2007 Jul; 9(7):459-64. PubMed ID: 17652060
[TBL] [Abstract][Full Text] [Related]
53. A multicentre phase-II feasibility study evaluating gemcitabine/vinorelbine / prednisolone combination chemotherapy in relapsed / refractory Hodgkin's lymphoma.
Naqi N; Ahmad S; Shah I; Khattak J
J Coll Physicians Surg Pak; 2013 Jun; 23(6):397-400. PubMed ID: 23763798
[TBL] [Abstract][Full Text] [Related]
54. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
55. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma.
Bass AJ; Gockerman JP; Hammett E; DeCastro CM; Adams DJ; Rosner GL; Payne N; Davis P; Foster T; Moore JO; Rizzieri DA
J Clin Oncol; 2002 Jul; 20(13):2995-3000. PubMed ID: 12089230
[TBL] [Abstract][Full Text] [Related]
56. Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study.
Pectasides D; Pectasides M; Farmakis D; Aravantinos G; Nikolaou M; Koumpou M; Gaglia A; Kostopoulou V; Mylonakis N; Skarlos D
Ann Oncol; 2004 Mar; 15(3):493-7. PubMed ID: 14998855
[TBL] [Abstract][Full Text] [Related]
57. The metronomic therapy with prednisone, etoposide, and cyclophosphamide reduces the serum levels of VEGF and circulating endothelial cells and improves response rates and progression-free survival in patients with relapsed or refractory non-Hodgkin's lymphoma.
Zeng J; Yang L; Huang F; Hong T; He Z; Lei J; Sun H; Lu Y; Hao X
Cancer Chemother Pharmacol; 2016 Oct; 78(4):801-8. PubMed ID: 27562137
[TBL] [Abstract][Full Text] [Related]
58. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen.
Takahashi T; Higashi S; Nishiyama H; Segawa T; Nakamura E; Kinoshita H; Itoh N; Yamamoto S; Kamoto T; Habuchi T; Ogawa O
Jpn J Clin Oncol; 2006 Feb; 36(2):104-8. PubMed ID: 16418182
[TBL] [Abstract][Full Text] [Related]
59. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma.
Dumontet C; Morschhauser F; Solal-Celigny P; Bouafia F; Bourgeois E; Thieblemont C; Leleu X; Hequet O; Salles G; Coiffier B
Br J Haematol; 2001 Jun; 113(3):772-8. PubMed ID: 11380469
[TBL] [Abstract][Full Text] [Related]
60. A randomized study comparing two different schedules of administration of cisplatin in combination with gemcitabine in advanced nonsmall cell lung carcinoma.
Ricci S; Antonuzzo A; Galli L; Tibaldi C; Bertuccelli M; Lopes Pegna A; Petruzzelli S; Bonifazi V; Orlandini C; Franco Conte P
Cancer; 2000 Oct; 89(8):1714-9. PubMed ID: 11042565
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]